Guillermo Cuervo, Marta Hernández-Meneses, Arístides de Alarcón, Rafael Luque-Marquez, María M Alonso-Socas, Ana López-Lirola, Víctor González-Ramallo, Ane J Goikoetxea-Agirre, David Nicolás, Miguel A Goenaga, Esperanza Merino, Francesc Escrihuela-Vidal, Pilar Martín-Dávila, Belén Loeches, Lucía Boix-Palop, Oriol Gasch, Marta Camprecios, Alicia Hernández-Torres, Lara García-Álvarez, Marcos Pajarón, María Angels Ribas, Rosa Blanes-Hernández, Inmaculada López-Montesinos, Luis E López-Cortés, Bárbara Vidal, Mariana Fernández-Pittol, Dolores Navarro, Asunción Moreno, Coral Sala, Juan Ambrosioni, José M Miró
{"title":"Oral vs. Outpatient Parenteral Antimicrobial Treatment for Infective Endocarditis: Study Protocol for the Spanish OraPAT-IE GAMES Trial.","authors":"Guillermo Cuervo, Marta Hernández-Meneses, Arístides de Alarcón, Rafael Luque-Marquez, María M Alonso-Socas, Ana López-Lirola, Víctor González-Ramallo, Ane J Goikoetxea-Agirre, David Nicolás, Miguel A Goenaga, Esperanza Merino, Francesc Escrihuela-Vidal, Pilar Martín-Dávila, Belén Loeches, Lucía Boix-Palop, Oriol Gasch, Marta Camprecios, Alicia Hernández-Torres, Lara García-Álvarez, Marcos Pajarón, María Angels Ribas, Rosa Blanes-Hernández, Inmaculada López-Montesinos, Luis E López-Cortés, Bárbara Vidal, Mariana Fernández-Pittol, Dolores Navarro, Asunción Moreno, Coral Sala, Juan Ambrosioni, José M Miró","doi":"10.1007/s40121-025-01110-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The POET trial demonstrated that moving from intravenous to oral antibiotics in stable patients with left-sided infective endocarditis (IE) was noninferior to fully parenteral treatment. However, it did not compare outpatient strategies.</p><p><strong>Methods: </strong>The OraPAT-IE GAMES trial is a noninferiority, multicenter, randomized, open-label study aimed to compare partial oral versus outpatient parenteral antibiotic therapy (OPAT) for consolidation of antibiotic treatment in left-sided IE. A total of 342 stable patients with IE caused by selected micro-organisms will eventually be included. After a minimum of 10 days of parenteral treatment, stable patients are randomized to oral therapy or OPAT. The primary end-point is a composite of all-cause mortality, unplanned cardiac surgery, relapse of positive blood cultures and/or unplanned hospital admission. Patients are followed-up for 6 months after completing antibiotic therapy.</p><p><strong>Planned outcome: </strong>This trial seeks to demonstrate the equivalent efficacy of the two outpatient strategies currently available for stable patients with IE in the consolidation phase of antibiotic treatment.</p><p><strong>Conclusion: </strong>In a global context of limited healthcare resources and a sustained increase in elderly and frail patients, it is of great importance to demonstrate the effectiveness and safety of outpatient management strategies that could reduce the duration of conventional hospitalizations with their potential complications and inherent costs.</p><p><strong>Trial registration: </strong>EudraCT: 2020-001024-34.</p><p><strong>Clinicaltrials: </strong>gov identifier: NCT05398679.</p>","PeriodicalId":13592,"journal":{"name":"Infectious Diseases and Therapy","volume":" ","pages":""},"PeriodicalIF":4.7000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious Diseases and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40121-025-01110-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: The POET trial demonstrated that moving from intravenous to oral antibiotics in stable patients with left-sided infective endocarditis (IE) was noninferior to fully parenteral treatment. However, it did not compare outpatient strategies.
Methods: The OraPAT-IE GAMES trial is a noninferiority, multicenter, randomized, open-label study aimed to compare partial oral versus outpatient parenteral antibiotic therapy (OPAT) for consolidation of antibiotic treatment in left-sided IE. A total of 342 stable patients with IE caused by selected micro-organisms will eventually be included. After a minimum of 10 days of parenteral treatment, stable patients are randomized to oral therapy or OPAT. The primary end-point is a composite of all-cause mortality, unplanned cardiac surgery, relapse of positive blood cultures and/or unplanned hospital admission. Patients are followed-up for 6 months after completing antibiotic therapy.
Planned outcome: This trial seeks to demonstrate the equivalent efficacy of the two outpatient strategies currently available for stable patients with IE in the consolidation phase of antibiotic treatment.
Conclusion: In a global context of limited healthcare resources and a sustained increase in elderly and frail patients, it is of great importance to demonstrate the effectiveness and safety of outpatient management strategies that could reduce the duration of conventional hospitalizations with their potential complications and inherent costs.
期刊介绍:
Infectious Diseases and Therapy is an international, open access, peer-reviewed, rapid publication journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of infectious disease therapies and interventions, including vaccines and devices. Studies relating to diagnostic products and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.
Areas of focus include, but are not limited to, bacterial and fungal infections, viral infections (including HIV/AIDS and hepatitis), parasitological diseases, tuberculosis and other mycobacterial diseases, vaccinations and other interventions, and drug-resistance, chronic infections, epidemiology and tropical, emergent, pediatric, dermal and sexually-transmitted diseases.